Leyden Laboratories B.V., an Amsterdam, The Netherlands-based company targeting commonalities of viral families to protect humanity from known and future viruses, closed a €40M Series A financing.
The round was led by GV (formerly Google Ventures), with participation from F-Prime Capital, Casdin Capital, LLC and Brook Byers. Concurrent with the financing, David Schenkein, M.D., general partner at GV, and Stephen Knight, M.D., president and managing partner at F-Prime, will join the board of directors.
The company intends to use the funds to further develop the platform and portfolio of product candidates and to build out the team.
Co-founded by Koenraad Wiedhaup, CEO, Jaap Goudsmit, CSO, Ronald Brus and Dinko Valerio (executive chair), Leyden Labs provides a platform that targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families.
The founding team is joined by a closely involved board of biotechnology leaders including John C. Martin, Onno van de Stolpe, James Shannon and Richard J. Whitley.